Search

Atherosclerosis is a chronic inflammatory disease that results in the formation of lipid-rich lesions and stiffening of arterial walls. An increasing body of evidence suggests that nearly all members of the leukocyte family accumulate within atherosclerosis-prone arteries and participate in various stages of disease progression. Recently, it has been proposed that progressive changes of the elastic modulus of the arterial wall during plaque development may directly influence the kinematics of leukocyte rolling. In the present study, we propose that rigidity sensing of rolling leukocytes may occur spontaneously due to the stiffness-dependent elastic instability of reversible bonds between rolling leukocytes and the arterial walls. This effect is mechanistic in nature and operates independently of cell biochemical signaling. To partially test this hypothesis, we measured the rolling velocities of functionalized microparticles, comparable in size to leukocytes, interacting with E-selectin coated substrates of controlled stiffness. The kinematic analysis of the particles' motion reveals a larger rolling velocity on softer substrates, aligning with previous reports regarding monocytes. A simple kinetic model for a cluster of reversible bonds formed between a cell and the underlying substrate demonstrates that the critical forces needed for bond disassembly decrease as substrate stiffness decreases. Consequently, bonds are more likely to break on softer substrates, resulting in enhanced cell mobility.

Summary: Mammals typically have hundreds of distinct olfactory sensory neuron subtypes, each defined by expression of a specific odorant receptor gene, which undergo neurogenesis throughout life at rates that can depend on olfactory experience. Here, we present a protocol to quantify the birthrates of specific neuron subtypes via the simultaneous detection of corresponding receptor mRNAs and 5-ethynyl-2′-deoxyuridine. For preparation prior to beginning the protocol, we detail procedures for generating odorant receptor-specific riboprobes and experimental mouse olfactory epithelial tissue sections.For complete details on the use and execution of this protocol, please refer to van der Linden et al. (2020).1 : Publisher’s note: Undertaking any experimental protocol requires adherence to local institutional guidelines for laboratory safety and ethics.

A paper analytic device, the chemoPAD, was developed and validated to visually detect methotrexate, doxorubicin, cisplatin, and oxaliplatin at concentrations commonly found in injectable dosage forms. By testing residual solution after patient treatment, the chemoPAD can be used to monitor drug quality without restriction of patient access to medication. The chemoPAD is produced by wax printing on Ahlstrom paper to create separate reaction areas and deposits small amounts of chemicals to create color changes in response to different active pharmaceutical ingredients (APIs). This creates a unique color bar code to identify each medication. Internal validation studies show that the chemoPAD has excellent sensitivity and specificity to differentiate between samples of 100% and 0% API, which is the distinction relevant to the majority of reported falsified chemotherapy cases. The platinum-containing drugs, cisplatin and oxaliplatin, can be detected semiquantitatively. The cards can be read either visually by comparison with a standard image or by using computer image analysis. Dosage forms were collected from the Ethiopian health care system and analyzed with the chemoPAD followed by high-performance liquid chromatography. A substandard sample was discovered and reported to the Ethiopian Food Medicine and Healthcare Administration and Control Authority.